Active Filter(s):
Details:
Under the agreement, Argo has granted Novartis exclusive global licenses to develop and commercialize a Phase 1 stage program. Novartis can select up to two targets against which Argo will perform discovery and optimization, to deliver PCCs.
Lead Product(s): BW-02
Therapeutic Area: Cardiology/Vascular Diseases Product Name: BW-02
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $4,165.0 million Upfront Cash: $185.0 million
Deal Type: Licensing Agreement January 07, 2024